Clinical Trials on Lung Neoplasms in China

Total 18749 results

Seagen Inc.

Recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Acute Myeloid Leukemia | FLT3-mutated Acute Myeloid Leukemia

Japan, Korea, Republic of, Taiwan
GlaxoSmithKline

Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Multiple Myeloma

China, Korea, Republic of, Australia, Italy, Spain, United States, Brazil, Czechia, France, Germany, Greece, Israel, Japan, New Zealand, Poland, Russian Federation, Turkey, United Kingdom
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)

Triple-Negative Breast Cancer

France, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
Hoffmann-La Roche
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical... and other collaborators

Completed

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)

Breast Cancer

France, Spain, Switzerland, Greece, Italy, Korea, Republic of, Australia, Canada, Poland, Belgium, United Kingdom, Netherlands, Germany, Chile, Ireland, Portugal, South Africa, Sweden, China, Austria, Hungary, Brazil, Colombia, Thailand, Denma... and more
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Colon Adenocarcinoma | Stage IIA Colon Cancer AJCC v8

United States, Canada, Puerto Rico
Boehringer Ingelheim

Completed

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Breast Neoplasms

Korea, Republic of, Spain, Canada, Germany, Singapore, China, United Kingdom, Taiwan, Israel, United States, Australia, Slovenia, Italy, Brazil, India, Czechia, Netherlands, Ireland, Poland, Belarus, Belgium, Portugal, Russian Federation and more
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
AstraZeneca

Active, not recruiting

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

United States, Italy, Spain, Belgium, Hungary, Poland, Canada, France, Germany, Korea, Republic of, Japan, Peru, Russian Federation, United Kingdom, China, Taiwan, Israel, Australia, Argentina
AstraZeneca
The Gynecologic Oncology Group (GOG) Foundation Inc; The European Network for...

Active, not recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Endometrial Neoplasms

United States, Belgium, Canada, Germany, Korea, Republic of, Brazil, Hungary, Japan, Poland, Russian Federation, China, Hong Kong, Spain, Israel, Australia, India, Singapore, Greece, Estonia, Lithuania, Mexico, Colombia
Hoffmann-La Roche

Terminated

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Renal Cell Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Argentina, Australia, Belgium, Brazil, China, Denmark, Ireland, Spain, Japan, Netherlands, Chile, Czechia, Italy, France, Israel, Turkey, Germany, Austria, Taiwan, Serbia, Poland, Thailan... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Belgium, Brazil, Canada, Chile, China, Estonia, France, Germany, Guatemala, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Philippines, Poland, Russian Federation, Singapore, Taiwan, Ukraine, United...
Novartis Pharmaceuticals

Completed

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

Metastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast Cancer

China, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)

Breast Cancer

United States, Korea, Republic of, United Kingdom, Australia, Belgium, China, Denmark, France, Hungary, Portugal, Spain, Taiwan, Thailand, Canada, Italy, Argentina, Brazil, Poland, Singapore, Germany, Greece, Hong Kong, Ukraine, Russian... and more
Eli Lilly and Company

Active, not recruiting

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Breast Cancer

Canada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
AstraZeneca

Active, not recruiting

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)

Hormone-Sensitive Prostate Cancer

United States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
Entasis Therapeutics

Completed

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex (ATTACK)

Bacteremia | Ventilator-associated Bacterial Pneumonia | Acinetobacter Baumannii-calcoaceticus Complex | Hospital-acquired Bacterial Pneumonia | Colistin Resistant ABC

United States, Belarus, Brazil, China, Greece, Hungary, India, Israel, Korea, Republic of, Lithuania, Mexico, Peru, Puerto Rico, Russian Federation, Taiwan, Thailand, Turkey
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Renal Cell Carcinoma (RCC)

Canada, France, United States, Spain, United Kingdom, Italy, Taiwan, Australia, Norway, Korea, Republic of, Germany, Russian Federation, Japan, Brazil, Turkey, Ukraine, Hungary, New Zealand, Chile, Ireland
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

Breast Cancer

Canada, Belgium, Korea, Republic of, United States, China, Taiwan, Mexico, Brazil, Argentina, Australia, Germany, Italy, Spain, Turkey, Thailand, South Africa, United Kingdom, France, Poland
Bio-Thera Solutions

Recruiting

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Optic Neuromyelitis Spectrum Disease

China
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Korea, Republic of, Spain, Canada, Brazil, China, Singapore, India, Turkey, Argentina, Australia, Belgium, Mexico, Finland, Hong Kong, South Africa, Italy, United Kingdom, France, Poland, Taiwan, Colombia, Germany
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Novartis Pharmaceuticals

Completed

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada, France, Italy, Spain, Belgium, Germany, Hungary, Saudi Arabia, Netherlands, Switzerland, Australia, Austria, Poland, Sweden, United Kingdom, Thailand, Korea, Republic of, Greece, Israel, Argentina, Japan, Colo... and more
Bayer

Completed

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)

Carcinoma, Transitional Cell

United States, Spain, Hungary, China, Belgium, Korea, Republic of, Taiwan, Australia, Singapore, Canada, Japan, Sweden, Russian Federation, Germany, Italy, Israel, Ireland, France, Austria, Denmark, Portugal, Switzerland, Czechia, Slo... and more
Children's Hospital of Chongqing Medical University

Completed

Target Weaning Oxygen to Determine Cafffeine Duration for AOP (DCAP)

Apnea of Prematurity | Caffeine | Weaning Oxygen | Medicine Regimen

China
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

Renal Cell Carcinoma

Korea, Republic of, Spain, United States, Netherlands, Ireland, Canada, United Kingdom, Poland, Italy, Australia, Russian Federation, Belgium, Israel, France, Greece, Czechia, Switzerland, Austria, Germany, Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Exelixis

Active, not recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

Renal Cell Carcinoma

United States, Japan, Brazil, Argentina, Australia, Chile, Czechia, Germany, Greece, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Spain, Turkey, United Kingdom
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer; HER2-positive; Metastatic

United States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Completed

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Breast Carcinoma | Cervical Carcinoma | Vaginal Carcinoma | Ovarian Carcinoma | Uterine Corpus Cancer | Vulvar Carcinoma | Postmenopausal

United States
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Active, not recruiting

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

Advanced or Metastatic Breast Cancer

United States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Poland, Taiwan, Russian Federation, Germany, Korea, Republic of, Brazil, Japan, Mexico, United Kingdom, China, Israel, Austria, Australia, Saudi Arabia, Netherl... and more
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Breast Cancer | Breast Neoplasms | HER2-positive Early Breast Cancer

United States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Poland, Australia, Canada, United States, Argentina, Austria, Belgium, Brazil, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, South Africa, Spain, Sweden, Switzerland, Turkey and more
Amgen

Completed

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, Taiwan, Hong Kong, China, India, Malaysia
GlaxoSmithKline

Completed

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Neoplasms, Prostate

United States, Australia, France, Germany, Spain, Bulgaria, Estonia, Italy, Poland, Netherlands, Belgium, United Kingdom, Canada, Denmark, Ukraine, Finland, Latvia, Russian Federation, Greece, Slovenia, Brazil, Mexico, Slovakia, Japan, Puerto... and more
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Cervical Cancer

Japan, United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Head and Neck Neoplasms

United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Endometrial Neoplasms

France, Canada, United States, Spain, United Kingdom, Italy, Taiwan, Korea, Republic of, Colombia, Australia, New Zealand, Brazil, Turkey, Poland, Israel, Argentina, Germany, Ireland, Japan, Mexico, Russian Federation
Astellas Pharma Global Development, Inc.
Seagen Inc.

Active, not recruiting

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Bladder Cancer | Urothelial Cancer | Ureteral Cancer

United States, Japan, Korea, Republic of, Taiwan, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, Switzerland, United Kingdom
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia

Clinical Trials on Lung Neoplasms in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations